University of Michigan Medical School-ko ikertzaileekin lankidetzan egindako argitalpenak (7)

2024

  1. AI is a viable alternative to high throughput screening: a 318-target study

    Scientific Reports, Vol. 14, Núm. 1

  2. Clinical outcomes after discontinuing anticoagulant therapy in patients with first unprovoked venous thromboembolism

    Journal of Thrombosis and Haemostasis, Vol. 22, Núm. 8, pp. 2234-2246

  3. Correction to: AI is a viable alternative to high throughput screening: a 318-target study (Scientific Reports, (2024), 14, 1, (7526), 10.1038/s41598-024-54655-z)

    Scientific Reports

2020

  1. Mortality prediction in chronic obstructive pulmonary disease comparing the gold 2015 and gold 2019 staging: A pooled analysis of individual patient data

    ERJ Open Research, Vol. 6, Núm. 4, pp. 1-10

2017

  1. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

    The Lancet, Vol. 389, Núm. 10088, pp. 2492-2502

2003

  1. Intrapulmonary expression of macrophage inflammatory protein 1α (CCL3) induces neutrophil and NK cell accumulation and stimulates innate immunity in murine bacterial pneumonia

    Infection and Immunity, Vol. 71, Núm. 3, pp. 1306-1315

2000

  1. The Ras family of GTPases in cancer cell invasion

    Cellular and Molecular Life Sciences, Vol. 57, Núm. 1, pp. 65-76